Skip to main content

02.05.2024 | Original Research Paper

Surface PD-1 expression in T cells is suppressed by HNRNPK through an exonic splicing silencer on exon 3

verfasst von: Jiayun Wang, Lingyan Yan, Xu Wang, Rong Jia, Jihua Guo

Erschienen in: Inflammation Research

Einloggen, um Zugang zu erhalten

Abstract

Objective

Immunotherapy targeting programmed cell death 1 (PDCD1 or PD-1) and its ligands has shown remarkable promise and the regulation mechanism of PD-1 expression has received arising attention in recent years. PDCD1 exon 3 encodes the transmembrane domain and the deletion of exon 3 produces a soluble protein isoform of PD-1 (sPD-1), which can enhance immune response by competing with full-length PD-1 protein (flPD-1 or surface PD-1) on T cell surface. However, the mechanism of PDCD1 exon 3 skipping is unclear.

Methods

The online SpliceAid program and minigene expression system were used to analyze potential splicing factors involved in the splicing event of PDCD1 exon 3. The potential binding motifs of heterogeneous nuclear ribonucleoprotein K (HNRNPK) on exon 3 predicted by SpliceAid were mutated by site-directed mutagenesis technology, which were further verified by pulldown assay. Antisense oligonucleotides (ASOs) targeting the exonic splicing silencer (ESS) on PDCD1 exon 3 were synthesized and screened to suppress the skipping of exon 3. The alternative splicing of PDCD1 exon 3 was analyzed by semiquantitative reverse transcription PCR. Western blot and flow cytometry were performed to detect the surface PD-1 expression in T cells.

Results

HNRNPK was screened as a key splicing factor that promoted PDCD1 exon 3 skipping, causing a decrease in flPD-1 expression on T cell membrane and an increase in sPD-1 expression. Mechanically, a key ESS has been identified on exon 3 and can be bound by HNRNPK protein to promote exon 3 skipping. Blocking the interaction between ESS and HNRNPK with an ASO significantly reduced exon 3 skipping. Importantly, HNRNPK can promote exon 3 skipping of mouse Pdcd1 gene as well.

Conclusions

Our study revealed a novel evolutionarily conserved regulatory mechanism of PD-1 expression. The splicing factor HNRNPK markedly promoted PDCD1 exon 3 skipping by binding to the ESS on PDCD1 exon 3, resulting in decreased expression of flPD-1 and increased expression of sPD-1 in T cells.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
3.
4.
Zurück zum Zitat Nielsen C, Ohm-Laursen L, Barington T, Husby S, Lillevang ST. Alternative splice variants of the human PD-1 gene. Cell Immunol. 2005;235(2):109–16.CrossRefPubMed Nielsen C, Ohm-Laursen L, Barington T, Husby S, Lillevang ST. Alternative splice variants of the human PD-1 gene. Cell Immunol. 2005;235(2):109–16.CrossRefPubMed
5.
Zurück zum Zitat Song MY, Park SH, Nam HJ, Choi DH, Sung YC. Enhancement of vaccine-induced primary and memory CD8(+) T-cell responses by soluble PD-1. J Immunother. 2011;34(3):297–306.CrossRefPubMed Song MY, Park SH, Nam HJ, Choi DH, Sung YC. Enhancement of vaccine-induced primary and memory CD8(+) T-cell responses by soluble PD-1. J Immunother. 2011;34(3):297–306.CrossRefPubMed
6.
Zurück zum Zitat Liu C, Jiang J, Gao L, Wang X, Hu X, Wu M, et al. Soluble PD-1 aggravates progression of collagen-induced arthritis through Th1 and Th17 pathways. Arthritis Res Ther. 2015;17:340.CrossRefPubMedPubMedCentral Liu C, Jiang J, Gao L, Wang X, Hu X, Wu M, et al. Soluble PD-1 aggravates progression of collagen-induced arthritis through Th1 and Th17 pathways. Arthritis Res Ther. 2015;17:340.CrossRefPubMedPubMedCentral
8.
Zurück zum Zitat Bommarito D, Hall C, Taams LS, Corrigall VM. Inflammatory cytokines compromise programmed cell death-1 (PD-1)-mediated T cell suppression in inflammatory arthritis through up-regulation of soluble PD-1. Clin Exp Immunol. 2017;188(3):455–66.CrossRefPubMedPubMedCentral Bommarito D, Hall C, Taams LS, Corrigall VM. Inflammatory cytokines compromise programmed cell death-1 (PD-1)-mediated T cell suppression in inflammatory arthritis through up-regulation of soluble PD-1. Clin Exp Immunol. 2017;188(3):455–66.CrossRefPubMedPubMedCentral
9.
Zurück zum Zitat Curran CS, Gupta S, Sanz I, Sharon E. PD-1 immunobiology in systemic lupus erythematosus. J Autoimmun. 2019;97:1–9.CrossRefPubMed Curran CS, Gupta S, Sanz I, Sharon E. PD-1 immunobiology in systemic lupus erythematosus. J Autoimmun. 2019;97:1–9.CrossRefPubMed
10.
Zurück zum Zitat Falcone M, Fousteri G. Role of the PD-1/PD-L1 dyad in the maintenance of pancreatic immune tolerance for prevention of type 1 diabetes. Front Endocrinol. 2020;11:569.CrossRef Falcone M, Fousteri G. Role of the PD-1/PD-L1 dyad in the maintenance of pancreatic immune tolerance for prevention of type 1 diabetes. Front Endocrinol. 2020;11:569.CrossRef
11.
Zurück zum Zitat Jia XH, Geng LY, Jiang PP, Xu H, Nan KJ, Yao Y, et al. The biomarkers related to immune related adverse events caused by immune checkpoint inhibitors. J Exp Clin Cancer Res. 2020;39(1):284.CrossRefPubMedPubMedCentral Jia XH, Geng LY, Jiang PP, Xu H, Nan KJ, Yao Y, et al. The biomarkers related to immune related adverse events caused by immune checkpoint inhibitors. J Exp Clin Cancer Res. 2020;39(1):284.CrossRefPubMedPubMedCentral
12.
Zurück zum Zitat Luoma AM, Suo S, Williams HL, Sharova T, Sullivan K, Manos M, et al. Molecular pathways of colon inflammation induced by cancer immunotherapy. Cell. 2020;182(3):655-71.e22.CrossRefPubMedPubMedCentral Luoma AM, Suo S, Williams HL, Sharova T, Sullivan K, Manos M, et al. Molecular pathways of colon inflammation induced by cancer immunotherapy. Cell. 2020;182(3):655-71.e22.CrossRefPubMedPubMedCentral
13.
Zurück zum Zitat Kobayashi M, Kawano S, Hatachi S, Kurimoto C, Okazaki T, Iwai Y, et al. Enhanced expression of programmed death-1 (PD-1)/PD-L1 in salivary glands of patients with Sjögren’s syndrome. J Rheumatol. 2005;32(11):2156–63.PubMed Kobayashi M, Kawano S, Hatachi S, Kurimoto C, Okazaki T, Iwai Y, et al. Enhanced expression of programmed death-1 (PD-1)/PD-L1 in salivary glands of patients with Sjögren’s syndrome. J Rheumatol. 2005;32(11):2156–63.PubMed
14.
Zurück zum Zitat Chen RY, Zhu Y, Shen YY, Xu QY, Tang HY, Cui NX, et al. The role of PD-1 signaling in health and immune-related diseases. Front Immunol. 2023;14:1163633.CrossRefPubMedPubMedCentral Chen RY, Zhu Y, Shen YY, Xu QY, Tang HY, Cui NX, et al. The role of PD-1 signaling in health and immune-related diseases. Front Immunol. 2023;14:1163633.CrossRefPubMedPubMedCentral
15.
Zurück zum Zitat Wan B, Nie H, Liu A, Feng G, He D, Xu R, et al. Aberrant regulation of synovial T cell activation by soluble costimulatory molecules in rheumatoid arthritis. J Immunol. 2006;177(12):8844–50.CrossRefPubMed Wan B, Nie H, Liu A, Feng G, He D, Xu R, et al. Aberrant regulation of synovial T cell activation by soluble costimulatory molecules in rheumatoid arthritis. J Immunol. 2006;177(12):8844–50.CrossRefPubMed
16.
Zurück zum Zitat Wu H, Chen L, Zhou X, Wu Y, Yan Y, Zhu Y, et al. Effect of tacrolimus on soluble costimulatory molecules in patients with refractory myasthenia gravis. J Neuroimmunol. 2022;372: 577955.CrossRefPubMed Wu H, Chen L, Zhou X, Wu Y, Yan Y, Zhu Y, et al. Effect of tacrolimus on soluble costimulatory molecules in patients with refractory myasthenia gravis. J Neuroimmunol. 2022;372: 577955.CrossRefPubMed
18.
Zurück zum Zitat Li D, Guo J, Jia R. Epigenetic control of cancer cell proliferation and cell cycle progression by HNRNPK via promoting exon 4 inclusion of histone code reader SPIN1. J Mol Biol. 2023;435(6): 167993.CrossRefPubMed Li D, Guo J, Jia R. Epigenetic control of cancer cell proliferation and cell cycle progression by HNRNPK via promoting exon 4 inclusion of histone code reader SPIN1. J Mol Biol. 2023;435(6): 167993.CrossRefPubMed
19.
Zurück zum Zitat Liu M, Lin C, Huang Q, Jia J, Guo J, Jia R. SRSF3-mediated Ki67 exon 7-inclusion promotes head and neck squamous cell carcinoma progression via repressing AKR1C2. Int J Mol Sci. 2023;24(4):3872.CrossRefPubMedPubMedCentral Liu M, Lin C, Huang Q, Jia J, Guo J, Jia R. SRSF3-mediated Ki67 exon 7-inclusion promotes head and neck squamous cell carcinoma progression via repressing AKR1C2. Int J Mol Sci. 2023;24(4):3872.CrossRefPubMedPubMedCentral
22.
Zurück zum Zitat Ito K, Sato K, Endo H. Cloning and characterization of a single-stranded DNA binding protein that specifically recognizes deoxycytidine stretch. Nucleic Acids Res. 1994;22(1):53–8.CrossRefPubMedPubMedCentral Ito K, Sato K, Endo H. Cloning and characterization of a single-stranded DNA binding protein that specifically recognizes deoxycytidine stretch. Nucleic Acids Res. 1994;22(1):53–8.CrossRefPubMedPubMedCentral
23.
Zurück zum Zitat Crooke ST, Baker BF, Crooke RM, Liang X-H. Antisense technology: an overview and prospectus. Nat Rev Drug Discov. 2021;20(6):427–53.CrossRefPubMed Crooke ST, Baker BF, Crooke RM, Liang X-H. Antisense technology: an overview and prospectus. Nat Rev Drug Discov. 2021;20(6):427–53.CrossRefPubMed
25.
Zurück zum Zitat Wang Z, Qiu H, He J, Liu L, Xue W, Fox A, et al. The emerging roles of hnRNPK. J Cell Physiol. 2020;235(3):1995–2008.CrossRefPubMed Wang Z, Qiu H, He J, Liu L, Xue W, Fox A, et al. The emerging roles of hnRNPK. J Cell Physiol. 2020;235(3):1995–2008.CrossRefPubMed
26.
Zurück zum Zitat Khan M, Zhao Z, Arooj S, Fu Y, Liao G. Soluble PD-1: predictive, prognostic, and therapeutic value for cancer immunotherapy. Front Immunol. 2020;11:587460.CrossRefPubMedPubMedCentral Khan M, Zhao Z, Arooj S, Fu Y, Liao G. Soluble PD-1: predictive, prognostic, and therapeutic value for cancer immunotherapy. Front Immunol. 2020;11:587460.CrossRefPubMedPubMedCentral
27.
Zurück zum Zitat Shin S, Seo H, Shin J, Park H, Lim D, Eom H, et al. Adenovirus expressing both thymidine kinase and soluble PD1 enhances antitumor immunity by strengthening CD8 T-cell response. Mol Ther. 2013;21(3):688–95.CrossRefPubMedPubMedCentral Shin S, Seo H, Shin J, Park H, Lim D, Eom H, et al. Adenovirus expressing both thymidine kinase and soluble PD1 enhances antitumor immunity by strengthening CD8 T-cell response. Mol Ther. 2013;21(3):688–95.CrossRefPubMedPubMedCentral
28.
Zurück zum Zitat Liu C, Jiang J, Gao L, Wang X, Hu X, Wu M, et al. Soluble PD-1 aggravates progression of collagen-induced arthritis through Th1 and Th17 pathways. Arthrit Res Ther. 2015;17:340.CrossRef Liu C, Jiang J, Gao L, Wang X, Hu X, Wu M, et al. Soluble PD-1 aggravates progression of collagen-induced arthritis through Th1 and Th17 pathways. Arthrit Res Ther. 2015;17:340.CrossRef
29.
Zurück zum Zitat Turunen J, Niemelä E, Verma B, Frilander M. The significant other: splicing by the minor spliceosome. Wiley Interdiscip Rev-RNA. 2013;4(1):61–76.CrossRefPubMed Turunen J, Niemelä E, Verma B, Frilander M. The significant other: splicing by the minor spliceosome. Wiley Interdiscip Rev-RNA. 2013;4(1):61–76.CrossRefPubMed
31.
Zurück zum Zitat Wang Z, Qiu H, He J, Liu L, Xue W, Fox A, et al. The emerging roles of hnRNPK. J Cell Physiol. 2020;235(3):1995–2008.CrossRefPubMed Wang Z, Qiu H, He J, Liu L, Xue W, Fox A, et al. The emerging roles of hnRNPK. J Cell Physiol. 2020;235(3):1995–2008.CrossRefPubMed
32.
Zurück zum Zitat Expert-Bezançon A, Le Caer J, Marie J. Heterogeneous nuclear ribonucleoprotein (hnRNP) K is a component of an intronic splicing enhancer complex that activates the splicing of the alternative exon 6A from chicken beta-tropomyosin pre-mRNA. J Biol Chem. 2002;277(19):16614–23.CrossRefPubMed Expert-Bezançon A, Le Caer J, Marie J. Heterogeneous nuclear ribonucleoprotein (hnRNP) K is a component of an intronic splicing enhancer complex that activates the splicing of the alternative exon 6A from chicken beta-tropomyosin pre-mRNA. J Biol Chem. 2002;277(19):16614–23.CrossRefPubMed
33.
Zurück zum Zitat Bampton A, Gatt A, Humphrey J, Cappelli S, Bhattacharya D, Foti S, et al. HnRNP K mislocalisation is a novel protein pathology of frontotemporal lobar degeneration and ageing and leads to cryptic splicing. Acta Neuropathol. 2021;142(4):609–27.CrossRefPubMedPubMedCentral Bampton A, Gatt A, Humphrey J, Cappelli S, Bhattacharya D, Foti S, et al. HnRNP K mislocalisation is a novel protein pathology of frontotemporal lobar degeneration and ageing and leads to cryptic splicing. Acta Neuropathol. 2021;142(4):609–27.CrossRefPubMedPubMedCentral
34.
Zurück zum Zitat Chen R, Zhu Y, Shen Y, Xu Q, Tang H, Cui N, et al. The role of PD-1 signaling in health and immune-related diseases. Front Immunol. 2023;14:1163633.CrossRefPubMedPubMedCentral Chen R, Zhu Y, Shen Y, Xu Q, Tang H, Cui N, et al. The role of PD-1 signaling in health and immune-related diseases. Front Immunol. 2023;14:1163633.CrossRefPubMedPubMedCentral
35.
Zurück zum Zitat Nishimura H, Nose M, Hiai H, Minato N, Honjo T. Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity. 1999;11(2):141–51.CrossRefPubMed Nishimura H, Nose M, Hiai H, Minato N, Honjo T. Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity. 1999;11(2):141–51.CrossRefPubMed
36.
Zurück zum Zitat Zamani M, Aslani S, Salmaninejad A, Javan M, Rezaei N. PD-1/PD-L and autoimmunity: a growing relationship. Cell Immunol. 2016;310:27–41.CrossRefPubMed Zamani M, Aslani S, Salmaninejad A, Javan M, Rezaei N. PD-1/PD-L and autoimmunity: a growing relationship. Cell Immunol. 2016;310:27–41.CrossRefPubMed
37.
Zurück zum Zitat Ding H, Wu X, Wu J, Yagita H, He Y, Zhang J, et al. Delivering PD-1 inhibitory signal concomitant with blocking ICOS co-stimulation suppresses lupus-like syndrome in autoimmune BXSB mice. Clin Immunol (Orlando, Fla). 2006;118:258–67.CrossRef Ding H, Wu X, Wu J, Yagita H, He Y, Zhang J, et al. Delivering PD-1 inhibitory signal concomitant with blocking ICOS co-stimulation suppresses lupus-like syndrome in autoimmune BXSB mice. Clin Immunol (Orlando, Fla). 2006;118:258–67.CrossRef
38.
39.
Zurück zum Zitat Cooper TA. Use of minigene systems to dissect alternative splicing elements. Methods. 2005;37(4):331–40.CrossRefPubMed Cooper TA. Use of minigene systems to dissect alternative splicing elements. Methods. 2005;37(4):331–40.CrossRefPubMed
41.
Zurück zum Zitat Coelho MB, Attig J, Bellora N, König J, Hallegger M, Kayikci M, et al. Nuclear matrix protein Matrin3 regulates alternative splicing and forms overlapping regulatory networks with PTB. Embo J. 2015;34(5):653–68.CrossRefPubMedPubMedCentral Coelho MB, Attig J, Bellora N, König J, Hallegger M, Kayikci M, et al. Nuclear matrix protein Matrin3 regulates alternative splicing and forms overlapping regulatory networks with PTB. Embo J. 2015;34(5):653–68.CrossRefPubMedPubMedCentral
Metadaten
Titel
Surface PD-1 expression in T cells is suppressed by HNRNPK through an exonic splicing silencer on exon 3
verfasst von
Jiayun Wang
Lingyan Yan
Xu Wang
Rong Jia
Jihua Guo
Publikationsdatum
02.05.2024
Verlag
Springer International Publishing
Erschienen in
Inflammation Research
Print ISSN: 1023-3830
Elektronische ISSN: 1420-908X
DOI
https://doi.org/10.1007/s00011-024-01887-4

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

29.05.2024 Herzinfarkt Nachrichten

Bei Menschen mit Typ-2-Diabetes sind die Chancen, einen Myokardinfarkt zu überleben, in den letzten 15 Jahren deutlich gestiegen – nicht jedoch bei Betroffenen mit Typ 1.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.